Evidence map›Paper›PMID 30474423›Full record

ArticleCirculation2018

Rapid Self-Assembly of Bioengineered Cardiovascular Bypass Grafts From Scaffold-Stabilized, Tubular Bilevel Cell Sheets.

Daniel von Bornstädt, Hanjay Wang, Michael J Paulsen, Andrew B Goldstone, Anahita Eskandari, Akshara Thakore, Lyndsay Stapleton, Amanda N Steele, Vi N Truong, Kevin Jaatinen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Engineered biomaterials for heart disease.Current opinion in biotechnology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Daniel von BornstädtDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.
Hanjay WangDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.
Michael J PaulsenDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.
Andrew B GoldstoneDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.
Anahita EskandariDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.
Akshara ThakoreDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.
Lyndsay StapletonDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.
Amanda N SteeleDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.
Vi N TruongDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.
Kevin JaatinenDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.
Camille HironakaDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.
Y Joseph WooDepartments of Cardiothoracic Surgery (D.v.B., H.W., M.J.P., A.B.G., A.E., A.T., L.S., A.N.S., V.N.T., K.J., C.H., Y.J.W.), Stanford University, CA.

Funding

ANGIOGENIC TISSUE ENGINEERING TO LIMIT POST-INFARCTION VENTRICULAR REMODELINGR01HL089315 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI WOO, Y JOSEPH · 2008 to 2023
$6.4M
NHLBI NIH HHS R01 HL089315
6 · The paper itself

Abstract

backgroundCardiovascular bypass grafting is an essential treatment for complex cases of atherosclerotic disease. Because the availability of autologous arterial and venous conduits is patient-limited, self-assembled cell-only grafts have been developed to serve as functional conduits with off-the-shelf availability. The unacceptably long production time required to generate these conduits, however, currently limits their clinical utility. Here, we introduce a novel technique to significantly accelerate the production process of self-assembled engineered vascular conduits.

methodsHuman aortic smooth muscle cells and skin fibroblasts were used to construct bilevel cell sheets. Cell sheets were wrapped around a 22.5-gauge Angiocath needle to form tubular vessel constructs. A thin, flexible membrane of clinically approved biodegradable tissue glue (Dermabond Advanced) served as a temporary, external scaffold, allowing immediate perfusion and endothelialization of the vessel construct in a bioreactor. Subsequently, the matured vascular conduits were used as femoral artery interposition grafts in rats (n=20). Burst pressure, vasoreactivity, flow dynamics, perfusion, graft patency, and histological structure were assessed.

resultsCompared with engineered vascular conduits formed without external stabilization, glue membrane-stabilized conduits reached maturity in the bioreactor in one-fifth the time. After only 2 weeks of perfusion, the matured conduits exhibited flow dynamics similar to that of control arteries, as well as physiological responses to vasoconstricting and vasodilating drugs. The matured conduits had burst pressures exceeding 500 mm Hg and had sufficient mechanical stability for surgical anastomoses. The patency rate of implanted conduits at 8 weeks was 100%, with flow rate and hind-limb perfusion similar to those of sham controls. Grafts explanted after 8 weeks showed a histological structure resembling that of typical arteries, including intima, media, adventitia, and internal and external elastic membrane layers.

conclusionsOur technique reduces the production time of self-assembled, cell sheet-derived engineered vascular conduits to 2 weeks, thereby permitting their use as bypass grafts within the clinical time window for elective cardiovascular surgery. Furthermore, our method uses only clinically approved materials and can be adapted to various cell sources, simplifying the path toward future clinical translation.

Indexed as

BioprosthesisBlood Vessel ProsthesisTissue ScaffoldsAnimalsAortaBlood Flow VelocityBlood Vessel Prosthesis ImplantationCells, CulturedCoculture TechniquesFemoral ArteryFibroblastsHumansMaleMuscle, Smooth, VascularMyocytes, Smooth MuscleProsthesis Designbioengineeringbioreactorscoronary artery bypasstissue adhesivevascular grafting

Identifiers

PMID30474423
PMCPMC6261325

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.